Croup: Straight To The Point of Care

Croup
Straight to the point of care
Last updated: Nov 15, 2019

Table of Contents
Overview 3
Summary 3
Definition 3
Theory 4
Epidemiology 4
Aetiology 4
Pathophysiology 4
Case history 4
Diagnosis 6
Approach 6
History and exam 6
Risk factors 8
Investigations 8
Differentials 9
Criteria 10
Management 12
Approach 12
Treatment algorithm overview 14
Treatment algorithm 15
Primary prevention 21
Secondary prevention 21
Patient discussions 21
Follow up 22
Monitoring 22
Complications 22
Prognosis 22
Guidelines 24
Diagnostic guidelines 24
Treatment guidelines 24
References 25
Disclaimer 34
Croup Overview
Summary
Common cause of acute respiratory distress in children.
Acute onset of seal-like barky cough in moderate to severe cases accompanied by stridor and sternal/
OVERVIEW
intercostal indrawing.
Careful history and physical examination sufficient for confirming clinical diagnosis and ruling out potentially
serious differentials.
Orally administered corticosteroids are the mainstay for all levels of severity, combined with nebulised
epinephrine (adrenaline) in moderate to severe croup to provide temporary relief of the symptoms of upper-
airway obstruction.
Definition
Croup, also known as laryngotracheobronchitis, is a common respiratory disease of childhood, characterised
by the sudden onset of a seal-like barky cough, often accompanied by stridor, voice hoarseness, and
respiratory distress. The symptoms are a result of upper-airway obstruction due to generalised inflammation
of the airways, as a result of viral infection (typically parainfluenza virus types 1 or 3).
This PDF of the BMJ Best Practice topic is based on the web version that was last updated: Nov 15, 2019.
BMJ Best Practice topics are regularly updated and the most recent version of the topics
3
can be found on bestpractice.bmj.com . Use of this content is subject to our disclaimer (.
Use of this content is subject to our) . © BMJ Publishing Group Ltd 2020. All rights reserved.
Croup Theory
Epidemiology
Croup is a frequent cause of acute respiratory distress in young children. Typically, it affects those between
6 months and 3 years of age, peaking in the second year of life. It has been reported to occur in infants
THEORY
younger than 6 months, in adolescents, and, more rarely, in adults.[1] [2] An observational study in a US
paediatric group practice found it to be the confirmed diagnosis in 15% of all cases of lower respiratory
infection.[1] Boys are more commonly affected, with a ratio of 1.4:1 compared with girls.[1] There is no
evidence to suggest variations in ethnicity prevalence. Admission rates peak in late autumn (September
through December), but cases occur all year round.[3] A peak in clinical presentations is correlated with
parainfluenza virus epidemics. These peaks typically occur in alternating years and result in a 50 % increase
in the number of children admitted with croup.[3]
Aetiology
The illness is due to viral infection (typically parainfluenza virus types 1 or 3).[3] Several other viral
pathogens have been recognised, including influenza A and B, adenovirus, respiratory syncytial virus,
metapneumovirus, coronavirus HCoV-NL63, and rarely measles.[1] [4] [5] [6] [7] [8] Distinctions have
been made between viral croup and spasmodic croup. However, it remains unclear as to whether these
entities represent different diseases or are merely a spectrum of the same disease. Clinically, it is difficult to
distinguish between the two, and is likely to be unnecessary as treatment decisions are based upon history
and clinical severity of the airway obstruction. Historically, laryngeal diphtheria was well known as a cause
of croup, but this is now rare in immunised populations. Reports of diphtheric croup have been published in
case series from India and Russia.[9] [10] [11] [12] A weak link between a history of previous intubation and
croup has been indicated.[13]
Pathophysiology
The symptoms result from upper-airway obstruction due to generalised inflammation and oedema of the
airways. At the cellular level this progresses to necrosis and shedding of the epithelium. The narrowed
subglottic region is responsible for the symptoms of seal-like barky cough, stridor (from increased airflow
turbulence), and sternal/intercostal indrawing. If the upper-airway obstruction worsens, respiratory failure can
result, leading to asynchronous chest and abdominal wall motion, fatigue, hypoxia, and hypercapnia.[14] [15]
[16]
Case history
Case history #1
A 2-year-old boy is brought to the emergency department by his parents in the middle of the night. He has
had mild symptoms of an upper respiratory infection for 48 hours, awoke with a sudden onset of seal-like
barky cough, and has had inspiratory stridor when crying. The stridor disappeared at rest, but the seal-
like barky cough has persisted.
4 This PDF of the BMJ Best Practice topic is based on the web version that was last updated: Nov 15, 2019.
Croup Theory
Case history #2
A 3-year-old boy is brought to the emergency department by his parents in the late evening. He has
developed a sudden onset of a seal-like barky cough, accompanied by clear nasal discharge. His parents
THEORY
became alarmed when he developed stridor, which persists throughout the trip to the hospital. On
examination, he has a seal-like barky cough and inspiratory stridor when at rest, which worsens with
agitation. Persistent sternal indrawing is also evident at rest.
5
Croup Diagnosis
Approach
The diagnosis of croup depends upon a careful history and physical examination. The key features are the
characteristic sudden-onset, seal-like barky cough, often accompanied by stridor and chest wall (intercostal)
or sternal indrawing. Symptoms are typically worse at night and increase with agitation.
There may be a history of prior non-specific upper respiratory tract symptoms (coryza, non-barky cough, mild
fever), although the seal-like barky cough may also present abruptly with no preceding illness. Although not
essential to the diagnosis, there is commonly a hoarse voice.
Clinical presentation
Presentations may range from mild symptoms to impending respiratory failure.[19] The physician should
look out for the following symptoms and signs according to severity:
• Mild: seal-like barky cough but no stridor or sternal/intercostal recession at rest

• Moderate: seal-like barky cough with stridor and sternal recession at rest; no agitation or lethargy
• Severe: seal-like barky cough with stridor and sternal/intercostal recession, associated with
agitation or lethargy
• Impending respiratory failure: increasing upper airway obstruction, sternal/intercostal recession,
asynchronous chest wall and abdominal movement, fatigue, and signs of hypoxia (pallor or
cyanosis) and hypercapnia (decreased level of consciousness secondary to rising PaCO₂). The
degree of chest wall recession may diminish with the onset of respiratory failure as the child tires.
The clinician must consider the differential diagnosis during the physical examination. In particular, if
epiglottitis is suspected, examination of the oropharynx or manipulation of the neck is contraindicated as it
may precipitate further airway obstruction.
Work-up
Croup is largely a clinical diagnosis.[20] X-ray of the anteroposterior and lateral neck is not performed in
a child presenting with typical symptoms and signs of croup. The steeple sign (narrowed trachea) is a
DIAGNOSIS
classic finding on anteroposterior view, but is not always present. Radiological studies are contraindicated
if there is clinical suspicion of epiglottitis or bacterial tracheitis, as manipulation of the neck region and
agitation may precipitate further airway obstruction. If the clinical picture is atypical for these conditions,
soft-tissue radiographs of the neck may provide helpful information to support an alternative diagnosis.
Any x-ray should be performed with considerable care and personnel equipped to support the airway in
the event of worsening obstruction.
History and exam

Key diagnostic factors
symptoms increasing with agitation (common)
• Seen in all levels of severity.
distinctive seal-like bark y cough (common)

• Key feature, required to make a diagnosis of croup.
age 6 months to 6 years (common)
Croup Diagnosis
• Occurs in this age group. Typically, it affects children between 6 months and 3 years of age, peaking in
the second year of life.[1]
• Croup can be seen in infants as young as 3 months of age, and may also occur, although rarely, in
older children, adolescents, and adults.[1]
Other diagnostic factors

male sex (common)
• Male to female ratio: 1.4:1.[1]
peak season late autumn (common)

• Cases peak in late autumn (September to December), which correlates with the peak prevalence of
parainfluenza virus in the community.[3]
prodromal symptoms (common)

• Non-specific upper respiratory tract symptoms (coryza, non-barky cough, mild fever) for 12 to 48 hours
may be present. Not a key feature in all cases; seal-like barky cough may present abruptly with no
preceding illness.
abrupt onset of symptoms (common)

• Typical, but not essential to the diagnosis.
symptoms worse at night (common)

• Typical, but not essential to the diagnosis.
hoarse voice (common)

• Not essential to the diagnosis, but commonly seen.
respiratory distress (sternal/intercostal indrawing, stridor) (uncommon)

• In moderate/severe croup.
DIAGNOSIS
persistent agitation (uncommon)
• In severe croup.
lethargy (uncommon)
• In severe croup (more likely in impending respiratory failure).
asynchronous chest wall and abdominal movement (uncommon)

• Impending respiratory failure.
fatigue (uncommon)
signs of hypoxia (pallor or cyanosis) (uncommon)

signs of hypercapnia (decreased level of consciousness secondary to rising

PaCO₂) (uncommon)
7
Croup Diagnosis
Risk factors
Strong
age 6 months to 6 years
• Occurs in this age group. Typically, it affects those between 6 months and 3 years of age, peaking in
the second year of life.[1]
• Croup can be seen in infants as young as 3 months of age, and may also occur, although rarely, in
older children, adolescents, and adults.[1]
Weak
male sex
• Male to female ratio: 1.4:1.[1]
prior intubation
• Small observational study indicates a weak link between a history of previous intubation and croup.[13]
Investigations
1st test to order
Test Result
clinical exam typical features on
clinical exam
• Croup is largely a clinical diagnosis.
Other tests to consider

DIAGNOSIS
Test Result
x-ray anteroposterior and lateral neck steeple sign in
anteroposterior view or
• Croup is largely a clinical diagnosis.Therefore, x-ray should not be
normal
performed in a child presenting with typical symptoms and signs of
croup. The steeple sign (narrowed trachea) is a classic finding on
anteroposterior view, but is not always present.
• Radiological studies are contraindicated if there is clinical suspicion of
epiglottitis or bacterial tracheitis, as manipulation of the neck region
and agitation may precipitate further airway obstruction. If the clinical
picture is atypical for these conditions, soft-tissue radiographs of
the neck may provide helpful information to support an alternative
diagnosis. Any x-ray should be performed with considerable care and
personnel equipped to support the airway in the event of worsening
obstruction.
Croup Diagnosis
Differentials
Condition Differentiating signs / Differentiating tests

symptoms
Bacterial tracheitis • May or may not have • Radiological studies are
antecedent symptoms contraindicated if there is
consistent with croup; clinical suspicion of bacterial
sudden deterioration tracheitis, as manipulation of
following 2 to 7 days of a the neck region and agitation
mild to moderate croup or may precipitate further
other mild viral illness;[14] airway obstruction.
fever, toxic appearance (child • Bronchoscopy, performed at
appears unwell and does the time of intubation, shows
not interact normally with erythematous tracheal
his/her surroundings) may mucosa, with thick, purulent
be present; painful cough; tracheal secretions.[25]
poor response to treatment • The most frequently
with nebulised epinephrine isolated pathogens
(adrenaline).[21] [22] [23] from tracheal secretions
[24] include Staphylococcus
aureus , group A
streptococcus, Moraxella
catarrhalis , Streptococcus
pneumoniae , Haemophilus
influenzae , and anaerobic
organisms.[14] [22] [23] [26]
[27] [28]
Epiglot titis • Rarely seen since • Radiological studies are

widespread immunisation contraindicated if there
against Haemophilus is clinical suspicion of
influenzae B;[29] [30] epiglottitis, as manipulation
[31] sudden onset of high of the neck region and
fever, dysphagia, drooling, agitation may precipitate
DIAGNOSIS
and anxiety; preferred further airway obstruction.
posture: sitting upright with • Visualisation of the
head extended; non-barky airway (prior to controlled
cough.[14] endotracheal intubation)
confirms the diagnosis
showing an oedematous,
erythematous epiglottis,
often obstructing the view of
the vocal cords.
Foreign body in the upper • Sudden onset of dyspnoea • Many foreign bodies are
airway and stridor; usually a clear not radio-opaque, thus x-
history of foreign body rays may not confirm the
inhalation or ingestion;[14] diagnosis.
no prodrome or symptoms of • Direct visualisation and
viral illness; no fever (unless removal of foreign body in
secondary infection).[32] the operating room confirms
the diagnosis.
Retropharyngeal abscess • Dysphagia, drooling, • Lateral neck radiograph may

occasionally stridor, demonstrate retroflexion
dyspnoea, tachypnoea, of cervical vertebrae and
9
Croup Diagnosis
Condition Differentiating signs / Differentiating tests

symptoms
neck stiffness, unilateral posterior pharyngeal
cervical adenopathy; onset is oedema.[33]
typically more gradual, often
accompanied by fever.[32]
Peritonsillar abscess • Dysphagia, drooling, • No differentiating tests.

occasionally stridor,
dyspnoea, tachypnoea,
neck stiffness, unilateral
cervical adenopathy; onset is
typically more gradual, often
accompanied by fever.[32]
Angioneurotic oedema • May present at any age; • No differentiating tests.

acute swelling of the upper
airway may cause dyspnoea
and stridor; fever uncommon.
Swelling of face, tongue, or
pharynx may be present.
Allergic reaction • May present at any age; • Allergy testing (skin prick
rapid onset of dysphagia, or RAST) may determine
stridor, and possible underlying allergen
cutaneous manifestations
(urticarial rash); often
personal or family history of
prior episodes or allergy.
Laryngeal diphtheria • Extremely rare clinical • No differentiating tests.

emergency. May present
at any age; history of
inadequate immunisation;
prodrome with symptoms
of pharyngitis for 2
DIAGNOSIS
to 3 days; low-grade
fever, voice hoarseness,
potentially barky cough;
dysphagia, inspiratory
stridor; characteristic
membranous pharyngitis on
examination.[32]
Congenital or acquired • Extremely rare. Usually • Upper airway endoscopy

tracheal or laryngeal presents at under 3 months or bronchoscopy will allow
abnormalities of age. direct visualisation of the
• Abnormally prolonged underlying abnormality.
or recurrent stridor. Poor However, these tests should
response to croup treatment. be delayed until after the
acute illness.
Criteria
Clinical classification of severity[19]
Croup Diagnosis
• Mild: seal-like barky cough but no stridor or sternal/intercostal recession at rest

• Moderate: seal-like barky cough with stridor and sternal recession at rest; no agitation or lethargy
• Severe: seal-like barky cough with stridor and sternal/intercostal recession associated with agitation or
lethargy
• Impending respiratory failure: increasing upper airway obstruction, sternal/intercostal recession,
asynchronous chest wall and abdominal movement, fatigue, and signs of hypoxia (pallor or cyanosis)
and hypercapnia (decreased level of consciousness secondary to rising PaCO₂). The degree of chest
wall recession may diminish with the onset of respiratory failure as the child tires.
Westley croup score: research classification

Total score ranging from 0 to 17 points. Five component items make up the score: [34]
• Stridor (0 = none, 1 = with agitation only, 2 = at rest)

• Recession (0 = none, 1 = mild, 2 = moderate, 3 = severe)
• Cyanosis (0 = none, 4 = cyanosis with agitation, 5 = cyanosis at rest)
• Level of consciousness (0 = normal - including asleep, 5 = disorientated)
• Air entry (0 = normal, 1 = decreased, 2 = markedly decreased).
The Westley croup score has been used in numerous clinical research studies to classify croup into mild,
moderate, and severe categories. A total score ≤1 is typically considered mild, 2 to 4 is considered moderate,
and a score ≥5 is considered severe.[35] However, substantial inter-observer variability exists when the score
is used in clinical practice, thus limiting its use in the clinical setting.[36]
DIAGNOSIS
11
Croup Management
Approach
In mild and moderate croup, the main goals of treatment are symptomatic relief; this is achieved with
supportive care and oral or nebulised corticosteroids. In moderate croup these should be combined
with nebulised epinephrine (adrenaline). Children may be safely discharged home after 2 to 4 hours of
observation following epinephrine administration.[37] [38] [39] [40] [41] [42] [43]
In severe croup, the main treatment aim is to prevent further airway compromise. In addition to the
combination treatment of nebulised or parenteral corticosteroids plus nebulised epinephrine, oxygen is
given to children demonstrating marked respiratory distress.[19] [44] [45] [46] [47] Intubation is indicated for
impending respiratory failure.[48] [49] [50] [51]
General care
Care should be taken to avoid frightening the child, as agitation may cause worsening of symptoms.[19]
To ensure comfort, the child should be seated comfortably in the carer's lap during assessment and
treatment. Although there is little research regarding the use of oxygen in croup, the clinical rationale is
clear in a child with significant respiratory distress. The mechanism by which patients with severe croup
become hypoxic is secondary to relative hypoventilation. Therefore, close monitoring and re-assessment
should occur continuously. Humidified oxygen may be administered via a plastic hose with the opening
held within a few centimetres of the nose or mouth to minimise the chance of causing agitation.[19] [44]
[45] [46] [47]
Especially in mild croup, parental assurance and education to the self-limited nature of the illness is
important.
Corticosteroids
Corticosteroids are the mainstay of medical treatment in mild, moderate, and severe croup.[38] [53]
[54] [55] [56] [57] [52] [58] In a systematic review, corticosteroids were found to improve symptoms of
moderate to severe croup within 2 hours, with the effect lasting for at least 24 hours.[59] Corticosteroid
were associated with an average 15-hour reduction in length of stay in hospital or emergency department,
and a 50% reduction in number of admissions for treatment and return visits.[59] However, most studies
were at high or unclear risk of bias.[59]
The usual administration is a single oral dose of dexamethasone, with treatment effect evident within
2 hours, and further beneficial effects noted up to 10 hours following initial dose.[38] Traditionally, a
dose of 0.6 mg/kg/dose was used for croup; however, evidence now supports the use of a smaller
dose of 0.15 mg/kg/dose. Adding inhaled budesonide does not appear to provide additional benefit.[64]
There is inadequate evidence comparing single versus multiple doses of corticosteroids. With most
croup symptoms showing resolution within 3 days of the onset, and the anti-inflammatory effect of
dexamethasone thought to last between 2 to 4 days, a second dose is unlikely to be beneficial in the
majority of children with croup.[65]
Both oral and intramuscular routes of administration have been shown to be equivalent or superior
MANAGEMENT
to inhaled corticosteroids in moderate to severe croup.[38] [55] [66] [67] [68] Alternative routes of
administration will be necessary in children who do not tolerate or absorb oral medicine (e.g., children
with persistent vomiting or severe respiratory distress). Inhaled budesonide may be preferable in children
with severe hypoxia, in whom reduced gut and tissue perfusion can impair oral and intramuscular
Croup Management
absorption. Establishing intravenous access can increase distress and potentially precipitate respiratory
failure. Extreme care should be taken when considering intravenous administration.
To date, no adverse effects have been attributed to the use of corticosteroids in children with croup.
Theoretical concerns include a possible increased risk of complications of varicella (bacterial
superinfection, disseminated varicella) in a child with recent exposure.
Adding nebulised epinephrine (adrenaline)

In moderate and severe croup, nebulised epinephrine should be administered with dexamethasone as
it provides temporary relief of symptoms of airway obstruction. [71] [72] A clear reduction in stridor and
sternal/intercostal recession should be evident within 10 to 30 minutes following administration.[38] The
clinical effects of nebulised epinephrine last on average at least 1 hour, but usually subside 2 hours
after administration.[34] On average, symptoms return to their baseline, without evidence of a rebound
effect.[74] [34] [75] [76] [77] [78]
Although racemic epinephrine has traditionally been used to treat children with croup, L-epinephrine is
as effective in moderate to severe croup.[79] In some countries, L-epinephrine availability may be limited.
The same dose of nebulised epinephrine is used regardless of weight, as the effective dose of drug
delivered to the airway is regulated by individual tidal volume.[80] [81] [82] [83] No adverse effects have
been noted when given one dose at a time.[79] [73] [74] [84] [60] [85] [86] Caution should be used with
multiple doses of nebulised epinephrine. There have been no reports of complications associated with the
use of L-epinephrine in children with known cardiac conditions. However, careful observation is advisable
if epinephrine treatment is deemed necessary.
In children who do not respond to combination treatment within a few hours following administration, a
refocused assessment should take place to rule out alternate diagnoses.
Impending respiratory failure

In children progressing to asynchronous chest wall and abdominal movement, fatigue, and signs of
hypoxia (pallor or cyanosis) and hypercapnia (decreased level of consciousness secondary to rising
PaCO₂), endotracheal intubation may be necessary to secure the airway.
Treatments with no added benefit

Historically mist or humidified air have been widely employed, but there is now convincing evidence that
these are ineffective[19] [88] [89] [90] [91] [92] [93] and even harmful in some instances. For example,
hot humidified air carries an increased risk of scald injuries[94] and mist tents promote mould growth if
improperly cleaned.[93] Additionally, being enclosed in a cold, wet space separated from the carer may
increase a child's agitation.
Antibiotics, beta-2 agonists, and decongestants have not been studied and their use should be
discouraged.[19] [44] [45] [46] [47]
Heliox (a defined mixture of helium and oxygen) has been studied as an adjunctive therapy in severe
airway obstruction.[85] [95] Helium is an inert gas that has no recognised pharmaceutical properties.
MANAGEMENT
Heliox usually contains 70% helium, limiting the fractional concentration of oxygen to maximal 30%.
Compared with nitrogen, the major gas found in room air, the lower-density helium gas decreases the
turbulence of airflow over the narrowed airways, which theoretically should result in decreased work of
breathing. However, heliox has not yet been shown to confer improvements over standard therapies,[96]
13
Croup Management
limits the fractional concentration of inhaled oxygen that can be provided and can be challenging to use in
unskilled hands.[85] [95] [97] [98] [99] [100] [101] [102] It is not currently recommended for use in children
with severe croup.
Tracheostomy is a rare intervention reserved for cases of unsuccessful endotracheal intubation (e.g.,
in severe epiglottitis) and is not indicated in croup. Its complications include risk of bleeding, damage
to adjacent structures in the neck, air leak (pneumomediastinum or pneumothorax), obstruction of the
tracheotomy tube, infection, and tracheal injury.
Treatment algorithm overview

Please note that formulations/routes and doses may differ between drug names and brands, drug
formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
Acute ( summary )
mild (no stridor at rest)
1st corticosteroids + supportive care
moderate (stridor at rest; no agitation

or lethargy)
plus nebulised adrenaline (epinephrine)
severe (stridor at rest with agitation

or lethargy)
plus supplemental ox ygen
with impending adjunct intubation

respiratory failure
MANAGEMENT
Croup Management
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug
formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
MANAGEMENT
15
Croup Management
Acute
mild (no stridor at rest)

Primary options
» dexamethasone: 0.15 to 0.6 mg/kg orally as

a single dose
» A single dose of oral dexamethasone is given

as soon as the clinical diagnosis of croup has
been made. Its effect in reducing the clinical
signs of croup is seen within 2 hours, with further
beneficial effects noted up to 10 hours following
administration.[38]
» Traditionally, a dose of 0.6 mg/kg/dose was

used for croup; however, evidence now supports
the use of a smaller dose of 0.15 mg/kg/dose.
» Care should be taken to avoid frightening

the child, as agitation may cause worsening of
symptoms.[19] Especially in mild croup, parental
assurance and education to the self-limited
nature of the illness is important.
» Historically mist or humidified air have been

widely employed, but there is now convincing
evidence that these are ineffective[19] [88] [89]
[90] [91] [92] [93] and even harmful in some
instances.
moderate (stridor at rest; no agitation
or lethargy)

Primary options

a single dose
OR
» budesonide inhaled: 2 mg nebulised as a

single dose
OR
» dexamethasone: 0.6 mg/kg intramuscularly

as a single dose

MANAGEMENT

signs of croup is seen within 2 hours, with further
beneficial effect noted up to 10 hours following
administration.[38]
Croup Management
Acute
» Nebulised budesonide is preferable in severe

hypoxia, persistent vomiting, or respiratory
distress preventing administration of an oral
dose.
» Intramuscular dexamethasone is another

alternative.
» Care should be taken to avoid frightening

the child, as agitation may cause worsening of
symptoms.[19] Historically mist or humidified
air have been widely employed, but there
is now convincing evidence that these are
ineffective[19] [88] [89] [90] [91] [92] [93] and
even harmful in some instances.
Treatment recommended for ALL patients in
selected patient group
Primary options
» adrenaline inhaled: (1:1000 solution of L-

adrenaline) 5 mL undiluted nebulised as a
single dose
OR
» adrenaline inhaled: (2.25% racemic

solution) 0.5 mL diluted to 2-4 mL with normal
saline nebulised as a single dose
» In children presenting with stridor, sternal

indrawing at rest, and persistent or increasing
agitation, nebulised adrenaline (epinephrine)
should be administered in addition to
dexamethasone. It provides temporary relief of
the airway obstruction while awaiting the effects
of corticosteroid treatment.[72]
» The clinical effects of nebulised adrenaline

(epinephrine) last on average at least 1 hour, but
usually subside 2 hours after administration.[34]
» The use of one dose at a time of nebulised

adrenaline (epinephrine) has not been
associated with any clinically significant
increases in BP or heart rate, neither has it been
MANAGEMENT
associated with any adverse events.[79] [73]

[74] [84] [60] [85] [86] Caution should be used
with multiple doses of nebulised adrenaline
(epinephrine). Careful observation is advisable
if adrenaline (epinephrine) treatment is deemed
necessary.
17
Croup Management
Acute
» Although racemic adrenaline (epinephrine)
has traditionally been used to treat children
with croup, L-adrenaline (epinephrine) is as
effective in moderate to severe croup.[79] In
some countries, L-adrenaline (epinephrine)
availability may be limited. The same dose is
used regardless of weight, as the effective dose
of drug delivered to the airway is regulated by
individual tidal volume.[80] [81] [82] [83]
severe (stridor at rest with agitation
or lethargy)

Primary options

a single dose
OR
» budesonide inhaled: 2 mg nebulised as a

single dose
OR
» dexamethasone: 0.6 mg/kg intramuscularly

as a single dose
Secondary options
» dexamethasone: 0.15 to 0.6 mg/kg

intravenously as a single dose

signs of croup is seen by 2 hours, with further
beneficial effect noted up to 10 hours following
administration.[38]

» Nebulised budesonide is preferable in severe

hypoxia, persistent vomiting or respiratory
distress preventing administration of an oral
dose.
» Intramuscular or intravenous dexamethasone

MANAGEMENT
is another alternative. However, there is

significant potential to increase agitation and
respiratory distress when an intravenous line is
inserted in a child with severe croup.
Croup Management
Acute
» Wherever possible, the child should be kept
in a calm environment with his/her caregiver.
Care should be taken to minimise interventions
that would increase the child’s agitation.
Historically mist or humidified air have been
widely employed, but there is now convincing
evidence that these are ineffective[19] [88] [89]
[90] [91] [92] [93] and even harmful in some
instances.
Primary options
» adrenaline inhaled: (1:1000 solution of L-

adrenaline) 5 mL undiluted nebulised as a
single dose
OR
» adrenaline inhaled: (2.25% racemic

solution) 0.5 mL diluted to 2-4mL with normal
saline nebulised as a single dose
» In children presenting with stridor, sternal/

intercostal indrawing at rest, and persistent
or increasing agitation, nebulised adrenaline
(epinephrine) should be administered in addition
to dexamethasone. It provides temporary relief of
the airway obstruction while awaiting the effects
of corticosteroid treatment.[72]
» The clinical effects of nebulised adrenaline

(epinephrine) last on average at least 1 hour, but
usually subside 2 hours after administration.[34]
» The use of one dose at a time of nebulised

adrenaline (epinephrine) has not been
associated with any clinically significant
increases in BP or heart rate; neither has it been
associated with any adverse events.[79] [73]
[74] [84] [60] [85] [86] Caution should be used
with multiple doses of nebulised adrenaline
(epinephrine).Careful observation is advisable
if adrenaline (epinephrine) treatment is deemed
necessary.
» Although racemic adrenaline (epinephrine)

has traditionally been used to treat children
with croup, L-adrenaline (epinephrine) is as
MANAGEMENT
effective in moderate to severe croup.[79] In

some countries, L-adrenaline (epinephrine)
availability may be limited. The same dose is
used regardless of weight, as the effective dose
of drug delivered to the airway is regulated by
individual tidal volume.[80] [81] [82] [83]
19
Croup Management
Acute
plus supplemental ox ygen
Primary options
» oxygen: 8 to 10 L/min blow-by
Secondary options
» oxygen: 100% by non-re-breather mask
» Humidified oxygen is given to children

demonstrating significant signs and symptoms
of respiratory distress, preferably as blow-by
oxygen via tubing held a few centimetres from
the child's nose and mouth.
» In the event that oxygenation is insufficient

using this method, 100% oxygen via a non-
re-breather mask is administered. However,
the application of the mask to the face carries
the potential for increasing agitation and
preparations (experienced personnel, intubation
equipment, medications) should be made to
secure the airway if the clinical situation worsens
to impending respiratory failure.
» Oxygen saturation monitoring should occur,

providing this does not increase the child's level
of agitation.
with impending adjunct intubation
respiratory failure
Treatment recommended for SOME patients in
» Indicated in children progressing to
asynchronous chest wall and abdominal
movement, fatigue, and signs of hypoxia (pallor
or cyanosis) and hypercapnia (decreased level
of consciousness secondary to rising PaCO₂).
» Becoming increasingly uncommon (in only

1% to 3% of children admitted with croup) and
performed as rapid sequence induction in a
controlled setting with experienced personnel
and equipment.[48] [49] [50] [51]
» Advisable to have a selection of endotracheal

tubes of smaller sizes at hand, as subglottic
oedema may cause difficulty when intubating
with a standard sized endotracheal tube.
MANAGEMENT
Croup Management
Primary prevention
No strategies for primary prevention are currently recommended. Work continues into the development of
an effective vaccine against the parainfluenza virus.[17] [18] If a vaccine were to become available, this may
lead to a significant reduction in croup caused by parainfluenza viruses.
Secondary prevention
In developing nations, vitamin A has been used as a preventive therapy for croup caused by severe
measles.[7] [8]
Patient discussions
Parents should be made aware of the symptoms and signs of croup:
• Hoarse voice
• Seal-like barking cough
• Stridor (a high-pitched crowing sound heard as child breathes in)
• Fever (although not all children will have a fever).
Most children with mild croup can be observed at home.
Parents should be advised to go to the hospital if:
• The crowing sound (stridor) can be heard continually

• The skin between the ribs is pulling in with every breath
• The child is restless or agitated.
Parents should be instructed to call an ambulance if:
• The child's face is very pale, blue, or grey (includes blue lips) for more than a few seconds
• The child is unusually sleepy or is not responding
• The child is having a lot of trouble breathing (e.g., the belly is sinking in while breathing, or the skin
between the ribs or over the windpipe is pulling in with each breath; the nostrils may also be flaring
in and out)
• The child is upset (agitated or restless) while struggling to breathe and cannot be calmed down
quickly
• The child wants to sit instead of lie down
• The child cannot talk, is drooling, or having trouble swallowing.
MANAGEMENT
21
Croup Follow up
Monitoring
Monitoring
FOLLOW UP
Children with moderate to severe croup responding well to combination therapy with corticosteroids and
nebulised epinephrine (adrenaline) (plus oxygen) may be safely discharged home after 2 to 4 hours of
observation following epinephrine administration.
Children admitted to hospital with significant respiratory distress despite therapy require continuous
monitoring and observation of respiratory status and vital signs.
In children who have undergone intubation, there is no need for subsequent follow-up after extubation,
once the respiratory distress and symptoms of upper-airway obstruction have resolved.
In the rare case of a child with persistent symptoms of upper-airway obstruction, re-evaluation should
occur to assess for pre-existing upper-airway anatomical abnormalities.
Complications
Complications Timeframe Likelihood

bacterial tracheitis short term low
Postulated mechanism is bacterial super-infection related to previously unknown immune dysfunction,

requiring treatment with broad-spectrum intravenous antibiotics and, in severe cases, endotracheal
intubation.[104]
pneumonia short term low
Postulated mechanism is bacterial super-infection, requiring treatment with broad-spectrum antibiotics.
Prognosis
Although most children with the condition suffer a mild and self-limited illness of short duration, the stress
and disruption experienced by the child and family are well documented.[103]
Mild
Self-limited without treatment but shorter time to resolution with dexamethasone treatment.
Moderate
Reasonable outlook. While symptoms of obstruction may be frightening, symptoms resolve without significant
complications.
Croup Follow up
Severe
Before corticosteroids became standard treatment, children with severe croup were 5 times more likely
to receive endotracheal intubation,[52] and remained intubated for 30% longer.[53] Introduction of routine
FOLLOW UP
corticosteroid treatment has dramatically decreased numbers of children intubated, reduced number of days
spent in ICU, and shortened length of hospital stay.[56] Since combination treatment with dexamethasone
and nebulised epinephrine (adrenaline) became standard care, prognosis for severe croup has been
excellent.
Impending respiratory failure

Very rare, with intubation required in only 1% to 3% of all cases.[48] [49] [50] [51]
23
Croup Guidelines
Diagnostic guidelines
International
Management of the child with cough or difficult breathing: a guide for low-
income countries (ht tps://www.theunion.org/what-we-do/publications/
technical)
Published by: International Union Against TB and Lung Disease Last published: 2005
North America
Acute management of croup in the emergency department (ht tps://

www.cps.ca/en/documents/authors-auteurs/acute-care-commit tee)
Published by: Canadian Paediatric Society Last published: 2017
GUIDELINES
Guideline for the diagnosis and management of croup (ht tps://

act t.albertadoctors.org/CPGs/Pages/default.aspx)
Published by: Alberta Medical Association Last published: 2015
Treatment guidelines
International
Management of the child with cough or difficult breathing: a guide for

low-income countries (ht tp://www.theunion.org/what-we-do/publications/
technical)
Published by: International Union Against TB and Lung Disease Last published: 2005
North America
Acute management of croup in the emergency department (ht tps://

www.cps.ca/en/documents/authors-auteurs/acute-care-commit tee)
Published by: Canadian Paediatric Society Last published: 2017
Guideline for the diagnosis and management of croup (ht tps://

act t.albertadoctors.org/CPGs/Pages/default.aspx)
Published by: Alberta Medical Association Last published: 2015
Croup References
Key articles
• Johnson D, Klassen T, Kellner J. Diagnosis and management of croup: Alberta Medical Association
REFERENCES
clinical practice guidelines. Alberta: Alberta Medical Association; 2015 [internet publication]. Full text
(https://www.topalbertadoctors.org/cpgs.php?sid=12&cpg_cats=35)
References
1. Denny FW, Murphy TF, Clyde WA Jr, et al. Croup: an 11-year study in a pediatric practice.
Pediatrics. 1983 Jun;71(6):871-6. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/6304611?
tool=bestpractice.bmj.com)
2. Tong MC, Chu MC, Leighton SE, et al. Adult croup. Chest. 1996 Jun;109(6):1659-62. Full text
(https://journal.publications.chestnet.org/data/Journals/CHEST/21733/1659.pdf) Abstract (http://
www.ncbi.nlm.nih.gov/pubmed/8769531?tool=bestpractice.bmj.com)
3. Marx A, Torok TJ, Holman RC, et al. Pediatric hospitalizations for croup (laryngotracheobronchitis):
biennial increases associated with human parainfluenza virus 1 epidemics. J Infect
Dis. 1997 Dec;176(6):1423-7 Abstract (http://www.ncbi.nlm.nih.gov/pubmed/9395350?
4. Chapman RS, Henderson FW, Clyde WA Jr, et al. The epidemiology of tracheobronchitis in
pediatric practice. Am J Epidemiol. 1981 Dec;114(6):786-97. Abstract (http://www.ncbi.nlm.nih.gov/
pubmed/6797294?tool=bestpractice.bmj.com)
5. Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract
disease in otherwise healthy infants and children. N Engl J Med. 2004 Jan 29;350(5):443-50. Abstract
(http://www.ncbi.nlm.nih.gov/pubmed/14749452?tool=bestpractice.bmj.com)
6. Van der Hoek L, Sure K, Ihorst G, et al. Human coronavirus NL63 infection is associated with croup.
Adv Exp Med Biol. 2006;581:485-91. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/17037582?
7. D'Souza RM, D'Souza R. Vitamin A for preventing secondary infections in children with measles
- a systematic review. J Trop Pediatr. 2002 Apr;48(2):72-7. Abstract (http://www.ncbi.nlm.nih.gov/
8. Hussey GD, Klein M. A randomized, controlled trial of vitamin A in children with severe measles.
N Engl J Med. 1990 Jul 19;323(3):160-4. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/2194128?
9. Havaldar PV. Dexamethasone in laryngeal diphtheritic croup. Ann Trop Paediatr. 1997 Mar;17(1):21-3.
Abstract (http://www.ncbi.nlm.nih.gov/pubmed/9176573?tool=bestpractice.bmj.com)
25
Croup References
10. Kapustian VA, Boldyrev VV, Maleev VV, et al. The local manifestations of diphtheria [in Russian].
Zh Mikrobiol Epidemiol Immunobiol. 1994 Jul-Aug;(4):19-22. Abstract (http://www.ncbi.nlm.nih.gov/
REFERENCES
11. Platonova TV, Korzhenkova MP. Clinical aspects of diphtheria in infants [in Russian]. Pediatriia. 1994
Jul-Aug;(4):19-22. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/1945649?tool=bestpractice.bmj.com)
12. Pokrovskii VI, Ostrovskii NN, Astaf'eva NV, et al. Croup in toxic forms of diphtheria in adults [in
Russian]. Ter Arkh. 1985;57(5):119-22. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/4023930?
13. Russell K. Risk factors for predicting severe croup and bacterial tracheitis (master's thesis). 2006.
Edmonton, AB: University of Alberta.
14. Cherry J. Croup (laryngitis, laryngotracheitis, spasmodic croup, laryngotracheobronchitis, bacterial

tracheitis, and laryngotracheobronchopneumonitis). In: Feigin R, ed. Textbook of pediatric infectious
diseases, 5th ed. Philadelphia, PA: Elsevier, 2004:252-65.
15. Davis G. An examination of the physiological consequences of chest wall distortion in infants with
croup. Calgary: University of Calgary, 1985.
16. Davis G, Cooper D, Mitchell I. The measurement of thoraco-abdominal asynchrony in infants

with severe laryngotracheobronchitis. Chest. 1993 Jun;103(6):1842-8. Full text (https://
journal.publications.chestnet.org/data/Journals/CHEST/21672/1842.pdf) Abstract (http://
17. Crowe JE Jr. Current approaches to the development of vaccines against disease caused
by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the
WHO Programme for Vaccine Development. Vaccine. 1995 Mar;13(4):415-21. Abstract (http://
18. Belshe RB, Newman FK, Anderson EL, et al. Evaluation of combined live, attenuated respiratory
syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J Infect Dis.
2004 Dec 15;190(12):2096-103. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/15551207?
19. Johnson D, Klassen T, Kellner J. Diagnosis and management of croup: Alberta Medical Association
clinical practice guidelines. Alberta: Alberta Medical Association; 2015 [internet publication]. Full text
(https://www.topalbertadoctors.org/cpgs.php?sid=12&cpg_cats=35)
20. Smith DK, McDermott AJ, Sullivan JF. Croup: diagnosis and management. Am Fam Physician. 2018
May 1;97(9):575-80. Full text (https://www.aafp.org/afp/2018/0501/p575.html) Abstract (http://
21. Sofer S, Duncan P, Chernick V. Bacterial tracheitis - an old disease rediscovered. Clin Pediatr
(Phila). 1983 Jun;22(6):407-11. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/6601559?
Croup References
22. Jones R, Santos JI, Overall JC Jr. Bacterial tracheitis. JAMA. 1979 Aug 24-31;242(8):721-6. Abstract
REFERENCES
23. Donnelly BW, McMillan JA, Weiner LB. Bacterial tracheitis: report of eight new cases and review.
Rev Infect Dis. 1990 Sep-Oct;12(5):729-35. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/2237109?
24. Al-Mutairi B, Kirk V. Bacterial tracheitis in children: approach to diagnosis and treatment. Paediatr
Child Health. 2004 Jan;9(1):25-30.
25. Kasian GF, Bingham WT, Steinberg J, et al. Bacterial tracheitis in children. CMAJ. 1989 Jan
1;140(1):46-50. Full text (https://www.pubmedcentral.nih.gov/pagerender.fcgi?artid=1268533)
26. Bernstein T, Brilli R, Jacobs B. Is bacterial tracheitis changing? A 14-month experience in a pediatric
intensive care unit. Clin Infect Dis. 1998 Sep;27(3):458-62. Abstract (http://www.ncbi.nlm.nih.gov/
27. Wong VK, Mason WH. Branhamella catarrhalis as a cause of bacterial tracheitis. Pediatr
Infect Dis J. 1987 Oct;6(10):945-6. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/3122157?
28. Brook I. Aerobic and anaerobic microbiology of bacterial tracheitis in children. Pediatr
Emerg Care. 1997 Feb;13(1):16-8. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/9061728?
29. Midwinter K, Hodgson D, Yardley M. Paediatric epiglottitis: the influence of the Haemophilus influenzae
b vaccine, a ten-year review in the Sheffield region. Clin Otolaryngol. 1999 Sep;24(5):447-8. Abstract
30. Gonzalez Valdepena H, Wald E, Rose E, et al. Epiglottitis and Haemophilus influenzae immunization:
the Pittsburgh experience - a five-year review. Pediatrics. 1995 Sep;96(3 Pt 1):424-7. Abstract (http://
31. Gorelick M, Baker M. Epiglottitis in children, 1979 through 1992. Effects of Haemophilus influenzae
type b immunization. Arch Pediatr Adolesc Med. 1994 Jan;148(1):47-50. Abstract (http://
32. Tunnessen W. Respiratory system: stridor - signs and symptoms in pediatrics. Philadelphia: JB
Lippincott, 1983.
33. Innes-Asher M. Infections of the upper respiratory tract. In: Taussig L, Landau L, eds. Pediatric
respiratory medicine. St Louis: Mosby, 1999: 530-47.
34. Westley CR, Cotton EK, Brooks JG. Nebulized racemic epinephrine by IPPB for the treatment
of croup: a double-blind study. Am J Dis Child. 1978 May;132(5):484-7. Abstract (http://
27
Croup References
35. Yang WC, Lee J, Chen CY, et al. Westley score and clinical factors in predicting the outcome of croup
in the pediatric emergency department. Pediatr Pulmonol. 2017 Oct;52(10):1329-34. Abstract (http://
REFERENCES
36. Chan AKJ, Langley JM, LeBlanc JC. Interobserver variability of croup scoring in clinical practice.
Paediatr Child Health. 2001 Jul;6(6):347-51.
37. Rizos JD, DiGravio BE, Sehl MJ, et al. The disposition of children with croup treated with
racemic epinephrine and dexamethasone in the emergency department. J Emerg Med. 1998 Jul-
Aug;16(4):535-9. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/9696166?tool=bestpractice.bmj.com)
38. Johnson DW, Jacobson S, Edney PC, et al. A comparison of nebulized budesonide,
intramuscular dexamethasone, and placebo for moderately severe croup. N Engl J Med.
1998 Aug 20;339(8):498-503. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/9709042?
39. Ledwith C, Shea L, Mauro R. Safety and efficacy of nebulized racemic epinephrine in conjunction
with oral dexamethasone and mist in the outpatient treatment of croup. Ann Emerg Med. 1995
Mar;25(3):331-7. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/7864472?tool=bestpractice.bmj.com)
40. Kunkel NC, Baker MD. Use of racemic epinephrine, dexamethasone, and mist in the
outpatient management of croup. Pediatr Emerg Care. 1996 Jun;12(3):156-9. Abstract (http://
41. Prendergast M, Jones JS, Hartman D. Racemic epinephrine in the treatment of laryngotracheitis: can
we identify children for outpatient therapy? Am J Emerg Med. 1994 Nov;12(6):613-6. Abstract (http://
42. Kelley PB, Simon JE. Racemic epinephrine use in croup and disposition. Am J Emerg Med. 1992
May;10(3):181-3. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/1375027?tool=bestpractice.bmj.com)
43. Corneli H, Bolte R. Outpatient use of racemic epinephrine in croup. Am Fam Physician. 1992
Sep;46(3):683-4. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/1514465?tool=bestpractice.bmj.com)
44. Kaditis AG, Wald ER. Viral croup: current diagnosis and treatment. Pediatr Infect Dis J. 1998
Sep;17(9):827-34. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/9779773?tool=bestpractice.bmj.com)
45. Klassen TP. Croup. A current perspective. Pediatr Clin North Am. 1999 Dec;46(6):1167-78. Abstract
46. Brown JC. The management of croup. Br Med Bull. 2002 Mar;61(1):189-202. Full text (https://
bmb.oxfordjournals.org/cgi/content/full/61/1/189) Abstract (http://www.ncbi.nlm.nih.gov/
47. Geelhoed GC. Croup. Pediatr Pulmonol. 1997 May;23(5):370-4. Abstract (http://www.ncbi.nlm.nih.gov/
Croup References
48. Sofer S, Dagan R, Tal A. The need for intubation in serious upper respiratory tract infection in
pediatric patients (a retrospective study). Infection. 1991 May-Jun;19(3):131-4. Abstract (http://
REFERENCES
49. Sendi K, Crysdale WS, Yoo J. Tracheitis: outcome of 1,700 cases presenting to the
emergency department during two years. J Otolaryngol. 1992 Feb;21(1):20-4. Abstract (http://
50. Tan AK, Manoukian JJ. Hospitalized croup (bacterial and viral): the role of rigid endoscopy. J
Otolaryngol. 1992 Feb;21(1):48-53. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/1564750?
51. Dawson KP, Mogridge N, Downward G. Severe acute laryngotracheitis in Christchurch 1980-90. N
Z Med J. 1991 Sep 11;104(919):374-5. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/1923075?
52. Kairys SW, Marsh-Olmstead EM, O'Connor GT. Steroid treatment of laryngotracheitis: a meta-
analysis of the evidence from randomized trials. Pediatrics. 1989 May;83(5):683-93. Abstract (http://
53. Tibballs J, Shann FA, Landau LI. Placebo-controlled trial of prednisolone in children intubated
for croup. Lancet. 1992 Sep 26;340(8822):745-8. Abstract (http://www.ncbi.nlm.nih.gov/
54. Klassen TP, Feldman ME, Watters LK, et al. Nebulized budesonide for children with mild-to-
moderate croup. N Engl J Med. 1994 Aug 4;331(5):285-9. Abstract (http://www.ncbi.nlm.nih.gov/
55. Geelhoed GC, Macdonald WB. Oral and inhaled steroids in croup: a randomized, placebo-
controlled trial. Pediatr Pulmonol. 1995 Dec;20(6):355-61. Abstract (http://www.ncbi.nlm.nih.gov/
56. Geelhoed GC. Sixteen years of croup in a Western Australian teaching hospital: effects of routine
steroid treatment. Ann Emerg Med. 1996 Dec;28(6):621-6. Abstract (http://www.ncbi.nlm.nih.gov/
57. Bjornson CL, Klassen TP, Williamson J, et al. A randomized trial of a single dose of oral
dexamethasone for mild croup. N Engl J Med. 2004 Sep 23;351(13):1306-13. Abstract (http://
58. Ortiz-Alvarez O. Acute management of croup in the emergency department. Paediatr Child Health.
2017 May 24;22(3):166-73. Full text (https://www.cps.ca/en/documents/position/acute-management-
of-croup) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/29532807?tool=bestpractice.bmj.com)
59. Gates A, Gates M, Vandermeer B, et al. Glucocorticoids for croup in children. Cochrane
Database Syst Rev. 2018 Aug 22;8:CD001955. Full text (https://www.cochranelibrary.com/
cdsr/doi/10.1002/14651858.CD001955.pub4/full) Abstract (http://www.ncbi.nlm.nih.gov/
29
Croup References
60. Chub-Uppakarn S, Sangsupawanich P. A randomized comparison of dexamethasone 0.15 mg/kg
versus 0.6 mg/kg for the treatment of moderate to severe croup. Int J Pediatr Otorhinolaryngol. 2007
Mar;71(3):473-7. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/17208307?tool=bestpractice.bmj.com)
REFERENCES
61. Geelhoed GC, Macdonald WB. Oral dexamethasone in the treatment of croup: 0.15 mg/kg
versus 0.3 mg/kg versus 0.6 mg/kg. Pediatr Pulmonol. 1995 Dec;20(6):362-8. Abstract (http://
62. Fifoot AA, Ting JY. Comparison between single-dose oral prednisolone and oral dexamethasone
in the treatment of croup: a randomized, double-blinded clinical trial. Emerg Med Australas. 2007
Feb;19(1):51-8. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/17305661?tool=bestpractice.bmj.com)
63. Alshehri M, Almegamsi T, Hammdi A. Efficacy of a small dose of oral dexamethasone in croup.
Biomedical Research. 2005 Jan 1;16(1):65-72.
64. Geelhoed GC. Budesonide offers no advantage when added to oral dexamethasone in the treatment
of croup. Pediatr Emerg Care. 2005 Jun;21(6):359-62. Abstract (http://www.ncbi.nlm.nih.gov/
65. Schimmer B, Parker K. Adrenocorticotropic hormone: adrenocortical steroids and their synthetic
analogs - inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton L, Lazo
J, Parker K, eds. Goodman and Gilman's the pharmacological basis of therapeutics. Columbus:
McGraw-Hill, 2006:1587-612.
66. Klassen TP, Craig WR, Moher D, et al. Nebulized budesonide and oral dexamethasone for
treatment of croup: a randomized controlled trial. JAMA. 1998 May 27;279(20):1629-32. Full text
(https://jama.ama-assn.org/cgi/content/full/279/20/1629) Abstract (http://www.ncbi.nlm.nih.gov/
67. Pedersen LV, Dahl M, Falk-Petersen HE, et al. Inhaled budesonide versus intramuscular
dexamethasone in the treatment of pseudo-croup [in Danish]. Ugeskr Laeger. 1998 Apr
6;160(15):2253-6. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/9599521?tool=bestpractice.bmj.com)
68. Cetinkaya F, Tufekci BS, Kutluk G. A comparison of nebulized budesonide, and intramuscular, and oral
dexamethasone for treatment of croup. Int J Pediatr Otorhinolaryngol. 22004 Apr;68(4):453-6. Abstract
69. Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics. 1993 Aug;92(2):223-8.
70. Patel H, Macarthur C, Johnson D. Recent corticosteroid use and the risk of complicated varicella in
otherwise immunocompetent children. Arch Pediatr Adolesc Med. 1996 Apr;150(4):409-14. Abstract
71. Adair JC, Ring WH, Jordan WS, et al. Ten-year experience with IPPB in the treatment of
acute laryngotracheobronchitis. Anesth Analg. 1971 Jul-Aug;50(4):649-55. Abstract (http://
Croup References
72. Bjornson C, Russell K, Vandermeer B, et al. Nebulized epinephrine for croup in children. Cochrane
Database Syst Rev. 2013 Oct 10;(10):CD006619. Full text (https://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD006619.pub3/full) Abstract (http://www.ncbi.nlm.nih.gov/
REFERENCES
73. Kristjansson S, Berg-Kelly K, Winso E. Inhalation of racemic adrenaline in the treatment of mild and
moderately severe croup. Clinical symptom score and oxygen saturation measurements for evaluation
of treatment effects. Acta Paediatr. 1994 Nov;83(11):1156-60. Abstract (http://www.ncbi.nlm.nih.gov/
74. Taussig LM, Castro O, Beaudry PH, et al. Treatment of laryngotracheobronchitis (croup). Use
of intermittent positive-pressure breathing and racemic epinephrine. Am J Dis Child. 1975
Jul;129(7):790-3. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/1096594?tool=bestpractice.bmj.com)
75. Steele DW, Santucci KA, Wright RO, et al. Pulsus paradoxus: an objective measure of severity in
croup. Am J Respir Crit Care Med. 1998 Jan;157(1):331-4. Full text (https://www.atsjournals.org/
doi/full/10.1164/ajrccm.157.1.9701071#.U3oQXD8hO3w) Abstract (http://www.ncbi.nlm.nih.gov/
76. Fanconi S, Burger R, Maurer H, et al. Transcutaneous carbon dioxide pressure for monitoring
patients with severe croup. J Pediatr. 1990 Nov;117(5):701-5. Abstract (http://www.ncbi.nlm.nih.gov/
77. Corkey CW, Barker GA, Edmonds JF, et al. Radiographic tracheal diameter measurements in acute
infectious croup: an objective scoring system. Crit Care Med. 1981 Aug;9(8):587-90. Abstract (http://
78. Gardner HG, Powell KR, Roden VJ, et al. The evaluation of racemic epinephrine in the treatment
of infectious croup. Pediatrics. 1973 Jul;52(1):52-5. Abstract (http://www.ncbi.nlm.nih.gov/
79. Waisman Y, Klein BL, Boenning DA, et al. Prospective randomized double-blind study comparing
L-epinephrine and racemic epinephrine aerosols in the treatment of laryngotracheitis (croup).
Pediatrics. 1992 Feb;89(2):302-6. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/1734400?
80. Janssens HM, Krijgsman A, Verbraak TF, et al. Determining factors of aerosol deposition for four
pMDI-spacer combinations in an infant upper airway model. J Aerosol Med. 2004 Spring;17(1):51-61.
81. Fink JB. Aerosol delivery to ventilated infant and pediatric patients. Respir Care.
2004 Jun;49(6):653-65. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/15165300?
82. Schuepp KG, Straub D, Moller A, et al. Deposition of aerosols in infants and children. J
Aerosol Med. 2004;17(2):153-6. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/15294065?
31
Croup References
83. Wildhaber JH, Monkhoff M, Sennhauser FH. Dosage regimens for inhaled therapy in children should
be reconsidered. J Paediatr Child Health. 2002 Apr;38(2):115-6. Abstract (http://www.ncbi.nlm.nih.gov/
REFERENCES
84. Fogel JM, Berg IJ, Gerber MA, et al. Racemic epinephrine in the treatment of croup: nebulization alone
versus nebulization with intermittent positive pressure breathing. J Pediatr. 1982 Dec;101(6):1028-31
85. Weber JE, Chudnofsky CR, Younger JG, et al. A randomized comparison of helium-oxygen mixture
(Heliox) and racemic epinephrine for the treatment of moderate to severe croup. Pediatrics. 2001
Jun;107(6):E96. Full text (https://pediatrics.aappublications.org/cgi/content/full/107/6/e96) Abstract
86. Zhang L, Sanguebsche LS. The safety of nebulization with 3 to 5 ml of adrenaline (1:1000)
in children: an evidence based review. J Pediatr (Rio J). 2005 May-Jun;81(3):193-7. Full text
(https://www.jped.com.br/conteudo/05-81-03-193/ing.asp) Abstract (http://www.ncbi.nlm.nih.gov/
87. Butte MJ, Nguyen BX, Hutchison TJ, et al. Pediatric myocardial infarction after racemic epinephrine
administration. Pediatrics. 1999;104:e9. Full text (http://pediatrics.aappublications.org/cgi/content/
full/104/1/e9) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/10390295?tool=bestpractice.bmj.com)
88. Henry R. Moist air in the treatment of laryngotracheitis. Arch Dis Child. 1983 Aug;58(8):577. Full text
(https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=6614970) Abstract
89. Lenney W, Milner AD. Treatment of acute viral croup. Arch Dis Child. 1978 Sep;53(9):704-6. Full text
(https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=718237) Abstract
90. Bourchier D, Dawson KP, Fergusson DM. Humidification in viral croup: a controlled trial. Aust
Paediatr J. 1984 Nov;20(4):289-91. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/6397182?
91. Skolnik N. Treatment of croup. A critical review. Am J Dis Child. 1989 Sep;143(9):1045-9. Abstract
92. Neto GM, Kentab O, Klassen TP, et al. A randomized controlled trial of mist in the acute treatment
of moderate croup. Acad Emerg Med. 2002 Sep;9(9):873-9. Abstract (http://www.ncbi.nlm.nih.gov/
93. Lavine E, Scolnik D. Lack of efficacy of humidification in the treatment of croup. Why do
physicians persist in using an unproven modality? CJEM. 2001 Jul;3(3):209-12. Abstract (http://
94. Greally P, Cheng K, Tanner MS, et al. Children with croup presenting with scalds. BMJ.
1990 Jul 14;301(6743):113. Full text (https://www.pubmedcentral.nih.gov/articlerender.fcgi?
Croup References
tool=pubmed&pubmedid=2390568) Abstract (http://www.ncbi.nlm.nih.gov/pubmed/2390568?
REFERENCES
95. Terregino CA, Nairn SJ, Chansky ME, et al. The effect of Heliox on croup: a pilot study. Acad
Emerg Med. 1998 Nov;5(11):1130-3. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/9835482?
96. Moraa I, Sturman N, McGuire TM, et al. Heliox for croup in children. Cochrane Database
Syst Rev. 2018 Oct 29;10:CD006822. Full text (https://www.cochranelibrary.com/cdsr/
doi/10.1002/14651858.CD006822.pub5/full) Abstract (http://www.ncbi.nlm.nih.gov/
97. Gupta VK, Cheifetz IM. Heliox administration in the pediatric intensive care unit: an evidence-
based review. Pediatr Crit Care Med. 2005 Mar;6(2):204-11. Abstract (http://www.ncbi.nlm.nih.gov/
98. Kemper KJ, Ritz RH, Benson MS, et al. Helium-oxygen mixture in the treatment of postextubation
stridor in pediatric trauma patients. Crit Care Med. 1991 Mar;19(3):356-9. Abstract (http://
99. Duncan PG. Efficacy of helium-oxygen mixtures in the management of severe viral and post-
intubation croup. Can Anaesth Soc J. 1979 May;26(3):206-12. Abstract (http://www.ncbi.nlm.nih.gov/
100. Beckmann KR, Brueggemann WM Jr. Heliox treatment of severe croup. Am J Emerg Med. 2000
Oct;18(6):735-6. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/11043633?tool=bestpractice.bmj.com)
101. McGee DL, Wald DA, Hinchliffe S. Helium-oxygen therapy in the emergency department. J
Emerg Med. 1997 May-Jun;15(3):291-6. Abstract (http://www.ncbi.nlm.nih.gov/pubmed/9258776?
102. DiCecco RJ, Rega PP. The application of heliox in the management of croup by an air
ambulance service. Air Med J. 2004 Mar-Apr;23(2):33-5. Abstract (http://www.ncbi.nlm.nih.gov/
103. Johnson D, Williamson J. Croup: duration of symptoms and impact on family functioning. Pediatr Res.
2001;49:83A.
104. Johnson DW, Schuh S, Koren G, et al. Outpatient treatment of croup with nebulized dexamethasone.
Arch Pediatr Adolesc Med. 1996 Apr;150(4):349-55. Abstract (http://www.ncbi.nlm.nih.gov/
33
Croup Disclaimer
Disclaimer
BMJ Best Practice is intended for licensed medical professionals. BMJ Publishing Group Ltd (BMJ) does not
advocate or endorse the use of any drug or therapy contained within this publication nor does it diagnose
patients. As a medical professional you retain full responsibility for the care and treatment of your patients
and you should use your own clinical judgement and expertise when using this product.
This content is not intended to cover all possible diagnosis methods, treatments, follow up, drugs and any
contraindications or side effects. In addition, since such standards and practices in medicine change as
new data become available, you should consult a variety of sources. We strongly recommend that you
independently verify specified diagnosis, treatments and follow-up and ensure it is appropriate for your
patient within your region. In addition, with respect to prescription medication, you are advised to check the
product information sheet accompanying each drug to verify conditions of use and identify any changes in
dosage schedule or contraindications, particularly if the drug to be administered is new, infrequently used, or
has a narrow therapeutic range. You must always check that drugs referenced are licensed for the specified
use and at the specified doses in your region.
Information included in BMJ Best Practice is provided on an “as is” basis without any representations,
conditions or warranties that it is accurate and up to date. BMJ and its licensors and licensees assume no
responsibility for any aspect of treatment administered to any patients with the aid of this information. To
the fullest extent permitted by law, BMJ and its licensors and licensees shall not incur any liability, including
without limitation, liability for damages, arising from the content. All conditions, warranties and other terms
which might otherwise be implied by the law including, without limitation, the warranties of satisfactory
quality, fitness for a particular purpose, use of reasonable care and skill and non-infringement of proprietary
rights are excluded.
Where BMJ Best Practice has been translated into a language other than English, BMJ does not warrant the
accuracy and reliability of the translations or the content provided by third parties (including but not limited to
local regulations, clinical guidelines, terminology, drug names and drug dosages). BMJ is not responsible for
any errors and omissions arising from translation and adaptation or otherwise.Where BMJ Best Practice lists
drug names, it does so by recommended International Nonproprietary Names (rINNs) only. It is possible that
certain drug formularies might refer to the same drugs using different names.
Please note that recommended formulations and doses may differ between drug databases drug names and
brands, drug formularies, or locations. A local drug formulary should always be consulted for full prescribing
information.
DISCLAIMER
Treatment recommendations in BMJ Best Practice are specific to patient groups. Care is advised when
selecting the integrated drug formulary as some treatment recommendations are for adults only, and external
links to a paediatric formulary do not necessarily advocate use in children (and vice-versa). Always check
that you have selected the correct drug formulary for your patient.
Where your version of BMJ Best Practice does not integrate with a local drug formulary, you should consult
a local pharmaceutical database for comprehensive drug information including contraindications, drug
interactions, and alternative dosing before prescribing.
Interpretation of numbers
Regardless of the language in which the content is displayed, numerals are displayed according to the
original English-language numerical separator standard. For example 4 digit numbers shall not include a
comma nor a decimal point; numbers of 5 or more digits shall include commas; and numbers stated to be
less than 1 shall be depicted using decimal points. See Figure 1 below for an explanatory table.
BMJ accepts no responsibility for misinterpretation of numbers which comply with this stated numerical
separator standard.
This approach is in line with the guidance of the International Bureau of Weights and Measures Service.
Figure 1 – BMJ Best Practice Numeral Style
Croup Disclaimer
5-digit numerals: 10,000
4-digit numerals: 1000
numerals < 1: 0.25
Our full website and application terms and conditions can be found here: Website Terms and Conditions.
Contact us
+ 44 (0) 207 111 1105

support@bmj.com
BMJ
BMA House
Tavistock Square
London
WC1H 9JR
UK
DISCLAIMER
35
Contributors:
// Authors:
Candice Bjornson, MSc, MD, FRCPC

Associate Professor
University of Calgary, Calgary, Canada
DISCLOSURES: CB declares that she has no competing interests. CB is the author of several references in
this topic.
David Johnson, MD
Professor
Department of Pediatrics and Physiology and Pharmacology, University of Calgary, Calgary, Canada
DISCLOSURES: DJ declares that he has no competing interests. DJ is the author of several references in
this topic.
// Peer Reviewers:
Jeffrey Chapman, MD
Staff
Department of Pulmonary and Critical Care Medicine, Cleveland Clinic, Cleveland, OH
DISCLOSURES: JC declares that he has no competing interests.
Ken Farion, MD
Assistant Professor
Pediatrics and Emergency Medicine, University of Ottawa, Ottawa, Canada
DISCLOSURES: KF declares that he has no competing interests.
Doreen Matsui, MD, FRCPC

Associate Professor
Departments of Paediatrics and Medicine, Children's Hospital of Western Ontario, London, Ontario, Canada
DISCLOSURES: DM declares that she has no competing interests.
Jeremy Hull, MBBS

Consultant Paediatrician
Children's Hospital and West Wing, John Radcliffe Hospital, Oxford, UK
DISCLOSURES: JH declares that he has no competing interests.
Steve Cunningham, MBBS, PhD

Consultant Respiratory Paediatrician
Department of Respiratory & Sleep Medicine, Royal Hospital for Sick Children, Edinburgh, UK
DISCLOSURES: SC declares that he has no competing interests.

Croup: Straight To The Point of Care

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Croup: Straight To The Point of Care

Uploaded by

Copyright:

Available Formats

Croup

Straight to the point of care

Last updated: Nov 15, 2019

• Mild: seal-like barky cough but no stridor or sternal/intercostal recession at rest

History and exam

distinctive seal-like bark y cough (common)

age 6 months to 6 years (common)

Other diagnostic factors

peak season late autumn (common)

prodromal symptoms (common)

abrupt onset of symptoms (common)

symptoms worse at night (common)

hoarse voice (common)

respiratory distress (sternal/intercostal indrawing, stridor) (uncommon)

asynchronous chest wall and abdominal movement (uncommon)

signs of hypoxia (pallor or cyanosis) (uncommon)

signs of hypercapnia (decreased level of consciousness secondary to rising

Other tests to consider

Condition Differentiating signs / Differentiating tests

Epiglot titis • Rarely seen since • Radiological studies are

Retropharyngeal abscess • Dysphagia, drooling, • Lateral neck radiograph may

Condition Differentiating signs / Differentiating tests

Peritonsillar abscess • Dysphagia, drooling, • No differentiating tests.

Angioneurotic oedema • May present at any age; • No differentiating tests.

Laryngeal diphtheria • Extremely rare clinical • No differentiating tests.

Congenital or acquired • Extremely rare. Usually • Upper airway endoscopy

• Mild: seal-like barky cough but no stridor or sternal/intercostal recession at rest

Westley croup score: research classification

• Stridor (0 = none, 1 = with agitation only, 2 = at rest)

Adding nebulised epinephrine (adrenaline)

Impending respiratory failure

Treatments with no added benefit

Treatment algorithm overview

1st corticosteroids + supportive care

moderate (stridor at rest; no agitation

1st corticosteroids + supportive care

plus nebulised adrenaline (epinephrine)

severe (stridor at rest with agitation

1st corticosteroids + supportive care

plus nebulised adrenaline (epinephrine)

plus supplemental ox ygen

with impending adjunct intubation

1st corticosteroids + supportive care

» dexamethasone: 0.15 to 0.6 mg/kg orally as

» A single dose of oral dexamethasone is given

» Traditionally, a dose of 0.6 mg/kg/dose was

» Care should be taken to avoid frightening

» Historically mist or humidified air have been

1st corticosteroids + supportive care

» dexamethasone: 0.15 to 0.6 mg/kg orally as

» budesonide inhaled: 2 mg nebulised as a

» dexamethasone: 0.6 mg/kg intramuscularly

» A single dose of oral dexamethasone is given

as soon as the clinical diagnosis of croup has

» Nebulised budesonide is preferable in severe

» Intramuscular dexamethasone is another

» Care should be taken to avoid frightening

» adrenaline inhaled: (1:1000 solution of L-

» adrenaline inhaled: (2.25% racemic

» In children presenting with stridor, sternal

» The clinical effects of nebulised adrenaline

» The use of one dose at a time of nebulised

associated with any adverse events.[79] [73]